August 6, 2013

Zoetis' Rui Lan An™ swine vaccine receives China's approval

Zoetis' joint venture in China has received the approval by China's Ministry of Agriculture for Rui Lan An™, a specialised vaccine to help control the highly pathogenic porcine reproductive and respiratory syndrome (HP PRRS).

Rui Lan An, which will be launched later this month, is the first vaccine to emerge from the joint venture that was established to develop and manufacture animal vaccines specifically designed for China's livestock producers. It will help China's pork producers meet increasing demand in China for quality, affordable pork.

"Our innovation starts with our customers and an understanding of their everyday animal health challenges. Rui Lan An exemplifies the commitment of our joint venture to develop and manufacture quality vaccines well matched to the local health challenges facing China's pork industry," said Stefan Weiskopf, executive vice president and president, Asia Pacific Region at Zoetis. "The vaccine represents our commitment to help assure a safe, sustainable food supply from healthy food production animals through global scientific expertise and local innovation. It is a key milestone for Zoetis' business in China."

Vaccines for swine have high growth potential as China is the world's leading pork producing nation, with an annual population of more than 685 million pigs in 2012. The joint venture provides a strategic platform for growth in China where the animal health industry is valued at US$1.8 billion and is expected to grow at 9.3% over year in the next 5 years.

Global animal health company Zoetis is built on a 60-year history as the animal health business of Pfizer. Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, with a focus on both farm and companion animals in 120 countries. In 2012, the company generated annual revenues of US$4.3 billion.